A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The Cardio-Oncology program at Northwestern offers care to cancer patients who develop
cardiac toxicities from chemotherapy. Breast cancer patients with the tumor marker for HER2
necessitate treatment with anthracycline and/or trastuzumab and pertuzumab-based
chemotherapies, which are known to cause cardiac toxicities. Breast cancer patients will
undergo a "cardio-oncology echocardiogram" which incorporates advanced left ventricular
assessment by utilizing deformation or strain imaging during chemotherapy treatment for
surveillance of cardiac toxicities. The aims of this project are:
1. To create a registry of both clinical, and echocardiographic variables, biomarkers, and
genetic analysis that will be used to develop a risk model to predict LV dysfunction in
early stage breast cancer patients undergoing chemotherapy with anthracycline and/or
trastuzumab and pertuzumab-based chemotherapy regimens.
2. To propose a new management algorithm for initiation of prophylactic beta-blocker
therapy for early stage breast cancer patients with preclinical cardiac toxicities
demonstrated by strain parameters.
3. To determine if initiation of prophylactic beta-blocker therapy in patients with early
cardiac toxicity can delay or prevent a drop in LV EF and the development of clinical
heart failure.
4. To explore serial measurements of a suite of novel biomarkers during ongoing anticancer
treatment that are presumed but not yet proven to be predictive of cardiac dysfunction
in women with breast cancer.
5. To identify DNA biomarkers of predilection to cardiotoxicity.
6. To generate hiPSC to validate markers predictive of cardiotoxicity.